Results 181 to 190 of about 15,581 (231)

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. [PDF]

Clin Cancer Res, 2021
Kim DH, Sun D, Storck WK, Welker Leng K, Jenkins C, Coleman DJ, Sampson D, Guan X, Kumaraswamy A, Rodansky ES, Urrutia JA, Schwartzman JA, Zhang C, Beltran H, Labrecque MP, Morrissey C, Lucas JM, Coleman IM, Nelson PS, Corey E, Handelman SK, Sexton JZ, Aggarwal R, Abida W, Feng FY, Small EJ, Spratt DE, Bankhead A, Rao A, Gesner EM, Attwell S, Lakhotia S, Campeau E, Yates JA, Xia Z, Alumkal JJ.   +35 more
europepmc   +1 more source

BET bromodomain inhibitors PFI-1 and CPI-203 suppress the development of follicular lymphoma via regulating Wnt/β-catenin signaling. [PDF]

Heliyon
Bai M, Huang Y, Suo X, Wang L, Han W, Zhang W.   +5 more
europepmc   +1 more source

BET bromodomain inhibition attenuates cardiac phenotype in myocyte-specific lamin A/C-deficient mice. [PDF]

J Clin Invest, 2020
Auguste G, Rouhi L, Matkovich SJ, Coarfa C, Robertson MJ, Czernuszewicz G, Gurha P, Marian AJ.   +7 more
europepmc   +1 more source

Bromodomain testis-specific (BRDT); bromodomain and extra terminal domain (BET) [PDF]

Science-Business eXchange, 2012
openaire   +1 more source

Zaiken MC, Flynn R, Paz KG, et al. BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. 2022;139(19):2983-2997.

Blood, 2023
europepmc   +1 more source

Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. [PDF]

Mol Cell, 2020
Shu S, Wu HJ, Ge JY, Zeid R, Harris IS, Jovanović B, Murphy K, Wang B, Qiu X, Endress JE, Reyes J, Lim K, Font-Tello A, Syamala S, Xiao T, Reddy Chilamakuri CS, Papachristou EK, D'Santos C, Anand J, Hinohara K, Li W, McDonald TO, Luoma A, Modiste RJ, Nguyen QD, Michel B, Cejas P, Kadoch C, Jaffe JD, Wucherpfennig KW, Qi J, Liu XS, Long H, Brown M, Carroll JS, Brugge JS, Bradner J, Michor F, Polyak K.   +38 more
europepmc   +1 more source

Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma. [PDF]

Mol Oncol, 2020
Song S, Li Y, Xu Y, Ma L, Pool Pizzi M, Jin J, Scott AW, Huo L, Wang Y, Lee JH, Bhutani MS, Weston B, Shanbhag ND, Johnson RL, Ajani JA.   +14 more
europepmc   +1 more source

Zinc-chelating BET bromodomain inhibitors equally target islet endocrine cell types.

Am J Physiol Regul Integr Comp Physiol
Jones Lipinski RA, Stancill JS, Nuñez R, Wynia-Smith SL, Sprague DJ, Nord JA, Bird A, Corbett JA, Smith BC.   +8 more
europepmc   +1 more source